https://doi.org/10.4081/monaldi.2020.1224
Edoxaban in elderly patient with morbid obesity and atrial fibrillation: the role of plasma levels evaluation for selecting the appropriate dose
Submitted: January 1, 2020
Accepted: February 4, 2020
Published: March 20, 2020
Accepted: February 4, 2020
Abstract Views: 1395
PDF: 845
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
We present the case of a 80-year-old man with atrial fibrillation, morbid obesity (weight 123 kg, height 167 cm, BMI 44.1), high clearance of creatinine and pharmacological polytherapy, in which the serial determinations of edoxaban plasma levels help us to choose the appropriate dose.
How to Cite
Russo, Vincenzo, Anna Rago, Nunzia Laezza, Pierpaolo Di Micco, Laura Giannetti, Luigi Atripaldi, Antonio D'Onofrio, Paolo Golino, and Gerardo Nigro. 2020. “Edoxaban in Elderly Patient With Morbid Obesity and Atrial Fibrillation: The Role of Plasma Levels Evaluation for Selecting the Appropriate Dose”. Monaldi Archives for Chest Disease 90 (1). https://doi.org/10.4081/monaldi.2020.1224.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
